Mangafodipir as an intracellular contrast agent in cardiac MRI

This research project focuses on the use of Mangafodipir as an intracellular contrast agent in cardiac MRI, for patients with heart failure with preserved ejection fraction (HFpEF) due to hypertrophic cardiomyopathy and cardiac amyloidosis. 

The project is interdisciplinary and involves different departments at Oslo University Hospital, Rikshospitalet, including the cardiac department, the clinic for radiology and nuclear medicine, and the intervention center.  Furthermore, it is a collaboration with IC Targets, a Norwegian company that holds the patent rights for the use of Mangafodipir for CMR applications, with funding from the Research Council of Norway. The overarching goal is to contribute to the development of a new tool in cardiac MRI, which can be implemented in clinical practice for the benefit of heart failure patients.

 

Last updated 7/10/2024